EGFR Mutations in non-Small Cell Lung Cancer

非小细胞肺癌中的 EGFR 突变

• 批准号: 7216360
• 负责人: BRUCE E. JOHNSON
• 金额: $ 28.05万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7216360
• 关键词: Accounting; Adenocarcinoma; Adenocarcinoma Cell; Aftercare; Behavior; Cancer Etiology; Cell Death; Cell Line; Cessation of life; Clinical; DNA Sequence; Data; Development; Disease; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Erlotinib; Event; Frequencies; Future; Gefitinib; Heterogeneity; In Vitro; In complete remission; Institution; Japan; Malignant neoplasm of lung; Mutation; Non-Small-Cell Lung Carcinoma; Outcome; Patients; Pharmacologic Substance; Point Mutation; Protein Tyrosine Kinase; Publications; Relapse; Research Personnel; Resistance; Signal Transduction; Smoker; Specimen; Stable Disease; Testing; Time; Tissues; Tumor Cell Line; Tyrosine Kinase Inhibitor; United States; Woman; chemotherapy; cohort; inhibitor/antagonist; lung Carcinoma; men; prospective; receptor; response; small molecule; tumor

DESCRIPTION (provided by applicant): Non-small cell lung carcinoma is responsible for approximately 85% of lung cancer and existing treatments for patients with advanced disease remain only marginally effective. Agents directed against the epidermal growth factor receptor have been developed (EGFR). However, only 10-20% of patients with relapsed non-small cell lung cancer have a partial or complete response to treatment with the common EGFR inhibitors, gefitinib and erlotinib. Point mutations and deletions in EGFR are associated with clinical responses to gefitinib in nearly all patients. Tumor cell lines with EGFR mutations are also sensitive to gefitinib treatment in vitro. This proposal is to further characterize the mutations in the EGFR in the tumors and tumor cell lines from subjects with non-small cell lung cancer. Aim 1 will be to establish the frequency and type of mutations in the epidermal growth factor receptor in previously untreated patients with advanced non-small cell lung cancer prospectively entered into trials using epidermal growth factor receptor inhibitors. We have two patient cohorts of 135 patients with advanced non-small cell lung cancer who are going to be studied. These cohorts will include those who respond to treatment, patients with stable disease, and patients with progressive non-small cell lung cancer. Aim 2 is to determine the relationship between epidermal growth factor receptor mutations, response to treatment, time to progression, and survival in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase. This will be done to determine if specific mutations give rise to different patient outcomes that include response, duration of response, and survival. We have assembled a consortium of investigators that have studied untreated patients with non-small cell lung cancer given single agent EGFR inhibitors to enable us to assemble multiple large groups of patients with responses and EGFR mutations. Aim 3 will be to study the tumors and tumor cell lines from patients with non-small cell lung cancer before and after treatment with EGFR inhibitors to determine the relationship between genetic changes and sensitivity and resistance to epidermal growth factor receptor inhibitors. NCI-H3255 and DFCI-LU- 011 are adenocarcinoma cell lines with EGFR mutations. Their sensitivity to EGFR inhibitors, downstream signaling events, and the mechanism of cell death compared to cell lines with wild type EGFR will be studied. These studies will provide guidance for future trials of EGFR inhibitors.

描述（由申请人提供）：非小细胞肺癌约占肺癌的 85%，现有治疗晚期疾病患者的效果仍然有限。已经开发出针对表皮生长因子受体（EGFR）的药物。然而，只有 10-20% 的复发性非小细胞肺癌患者对常见 EGFR 抑制剂吉非替尼和厄洛替尼的治疗有部分或完全缓解。 EGFR 点突变和缺失与几乎所有患者对吉非替尼的临床反应相关。具有 EGFR 突变的肿瘤细胞系对体外吉非替尼治疗也敏感。该提案旨在进一步表征非小细胞肺癌受试者的肿瘤和肿瘤细胞系中 EGFR 的突变。目标 1 是确定先前未经治疗的晚期非小细胞肺癌患者中表皮生长因子受体突变的频率和类型，前瞻性地进入使用表皮生长因子受体抑制剂的试验。我们将研究两个由 135 名晚期非小细胞肺癌患者组成的患者队列。这些队列将包括对治疗有反应的患者、疾病稳定的患者以及进展性非小细胞肺癌患者。目标 2 是确定表皮生长因子受体酪氨酸激酶治疗的非小细胞肺癌患者的表皮生长因子受体突变、治疗反应、进展时间和生存之间的关系。这样做是为了确定特定突变是否会导致不同的患者结果，包括反应、反应持续时间和生存。我们组建了一个研究人员联盟，对未经治疗的非小细胞肺癌患者进行单药 EGFR 抑制剂治疗的研究，使我们能够聚集多个有反应和 EGFR 突变的大组患者。目标 3 将研究非小细胞肺癌患者接受 EGFR 抑制剂治疗前后的肿瘤和肿瘤细胞系，以确定基因变化与表皮生长因子受体抑制剂敏感性和耐药性之间的关系。 NCI-H3255和DFCI-LU-011是具有EGFR突变的腺癌细胞系。将研究与野生型 EGFR 细胞系相比，它们对 EGFR 抑制剂的敏感性、下游信号事件以及细胞死亡机制。这些研究将为未来EGFR抑制剂的试验提供指导。